The global biosimilars market is projected to reach $74 billion by 2026, growing at a CAGR of 18.3%. The expiry of key biologics patents is opening vast commercial opportunities for CDMO partners and generics manufacturers.
Key Market Trends
In the US, biosimilar adoption has driven reference product pricing down by up to 70% in some payer contracts. Europe continues to lead adoption, with biosimilar penetration exceeding 80% in oncology segments in Germany and the UK.
Supply Chain Implications
Manufacturers are investing heavily in high-capacity bioreactor facilities. CDMOs with single-use bioreactor technology and integrated analytical services are gaining market share.